Compare BIRK & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIRK | ROIV |
|---|---|---|
| Founded | 1774 | 2014 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 14.1B |
| IPO Year | 2023 | N/A |
| Metric | BIRK | ROIV |
|---|---|---|
| Price | $41.84 | $21.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $64.69 | $24.31 |
| AVG Volume (30 Days) | 2.9M | ★ 8.2M |
| Earning Date | 02-19-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.10 | N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $2,460,904,611.00 | $20,329,000.00 |
| Revenue This Year | $14.52 | N/A |
| Revenue Next Year | $14.40 | $741.42 |
| P/E Ratio | $18.66 | ★ N/A |
| Revenue Growth | ★ 16.22 | N/A |
| 52 Week Low | $38.16 | $8.73 |
| 52 Week High | $62.66 | $23.47 |
| Indicator | BIRK | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 56.28 |
| Support Level | $40.68 | $21.36 |
| Resistance Level | $43.02 | $22.72 |
| Average True Range (ATR) | 1.70 | 0.72 |
| MACD | -0.39 | -0.13 |
| Stochastic Oscillator | 23.86 | 32.69 |
Birkenstock Holding PLC is a company that manufactures and sells footbed-based products, including sandals, closed-toe silhouettes, and other products, such as skincare and accessories, for everyday, leisure, and work. It sells its products through two main channels: business-to-business (B2B) which comprises sales made to established third-party store networks, and direct-to-consumer (DTC) which comprises sales made on globally owned online stores through the Birkenstock.com domain and sales made in Birkenstock retail stores. The company's reportable segments are based on its regional hubs and include: the Americas which is also its key revenue-generating segment; Europe; and Australia, Japan, India, China, and the United Arab Emirates (APMA).
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.